The numbers explain why peptides are attracting so much attention.
🔹One market estimate places the global peptide therapeutics market at $140.9 billion in 2025
🔹It is projected to reach $294.6 billion by 2033
🔹That implies an 8.7% CAGR
🔹Metabolic disorders accounted for the largest application share in this estimate
👉 The exact market size varies depending on methodology. But the direction is clear: peptides are becoming a significant pharma platform.
GLP-1 may be the catalyst, but it is unlikely to be the entire story.
🔹Semaglutide and tirzepatide demonstrated the commercial potential of peptide-based medicines
🔹The pipeline is expanding into dual agonists, multi-agonists and next-generation metabolic therapies
🔹In India, one estimate projects the GLP-1 market to grow from $240.5 million in 2026 to ~$1 billion by 2033
🔹India's anti-obesity drug market has also seen rapid growth alongside GLP-1 adoption
👉 The question is whether this demand creates a lasting manufacturing ecosystem.
The peptide value chain is far more layered than a conventional API story.
🔹Amino acids
🔹Protected amino acids & resins
🔹Peptide fragments
🔹Peptide synthesis
🔹Purification & isolation
🔹Peptide API
🔹Sterile fill-finish
🔹Cartridges, syringes & injection devices
👉 Not every company entering peptides will participate across this entire chain. And that difference could determine where the economics ultimately accrue.
The real competitive advantage may lie in the difficult steps, not simply in having "peptide capability."
🔹Long peptides require multiple sequential synthesis steps
🔹Small inefficiencies can compound as molecular complexity increases
🔹Purification requires separating the desired molecule from closely related impurities
🔹Commercial manufacturing also requires analytical, regulatory and scale-up expertise
👉 The industry is already facing capacity constraints across peptide APIs, sterile fill-finish, injector devices and glass cartridges.
Indian companies are entering the opportunity from very different points in the value chain.
🔹Divi's Laboratories → Building blocks, intermediates and peptide manufacturing integration
🔹Blue Jet Healthcare → Upstream peptide building blocks
🔹Neuland Laboratories → Complex peptide CDMO and commercial-scale synthesis
🔹Laurus Labs → Expanding peptide capabilities within a broader CDMO platform
🔹Sai Life Sciences → Discovery, development and peptide services
👉 The key is to differentiate between announced capability, development capacity and commercial-scale manufacturing.
Stock Fundamental in detail
@Fundamental3
1September 4, 2026 1.4K 10
